Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.

Rivastigmine

  Cat. No.:  DC25088   Featured
Chemical Structure
123441-03-2
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86 21 58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
An acetylcholinesterase (AChE) inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Cas No.: 123441-03-2
Chemical Name: Rivastigmine
Synonyms: Rivastigmine;EXELON;RIVASTIGMINE HYDROGEN TARTRATE;RIVASTIGIMINE(FORR&DONLY);3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate;Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester;(S)-Rivastigmine;S-Rivastigmine;(+)-rivastigmine;(S)-3-[1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate;AC1L2U92;BIDD:GT0316;CHEBI:8874;CHEMBL636;ENA 713 free base;Rivastigmine [USAN:INN];rivastigmine free base;S-N-ethyl-3-[1-(dimethylamino)ethyl]-N-methyl-phenylcarbamate;UNII-PKI06M3IW0;USAN;N-Ethyl-N-methylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl-ester;Revastigmine;RivastigiMine;Rivastigmine (0.1 mL);Rivastigmine Base;Tartrate;RIVASTIGMINE (USP MONOGRAPH);ENA-713D;Carbamic acid, ethylmethyl-, 3-(1-(dimethylamino)ethyl)phenyl ester, (S)-;R0250;rivastigmine hexal;2,3-dihydroxybutanedioic acid; 3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate;AC-8250;XSVMFMHYUFZWBK-NSHDSACASA-N;RIVASTIGMINE [USAN];AB01275472_02;AMY3808;HMS3885B18;RIVASTIGMINE [ORANGE BOOK];RIVASTIGMINE [VANDF];SMR002203623;Ethyl-methyl-carbamic acid 3-(1-dimethylamino-ethyl)-phenyl ester;SDZ-212-713;MFCD00871496;Ethyl-methyl-carbamic acid 3-((R)-1-dimethylamino-ethyl)-phenyl ester;NCGC00167531-03;SR-05000001475;AS-73448;ethylmethylcarbamic acid 3-[1-(dimethylamino)ethyl]phenyl ester;Ethyl-methyl-carbamic acid 3-((S)-1-dimethylamino-ethyl)-phenyl ester;RIVASTIGMINE [WHO-DD];Rivastigmine Transdermal System;RIVASTIGMINE (MART.);RIVASTIGMINE [MI];S4687;Q411887;RIVASTIGMINE (EP MONOGRAPH);D03822;SDZ-212713;RIVASTIGMINE [EP MONOGRAPH];BDBM10620;SDZ ENA 713;SDZ 212-713;RIVASTIGMINE [JAN];Rivastigmine Teva;3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate;RIVASTIGMINE [EMA EPAR];BDBM11682;PKI06M3IW0;3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate;N06DA03;Exelon;rivastigminum;Carbamic acid, N-ethyl-N-methyl-, 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester;EN300-7403044;HMS3715P15;AKOS015896334;HY-17368;MLS003876822;AB01275472_03;DTXSID7023564;Rivastigmine [USAN:INN:BAN:JAN];Carbamic acid, ethylmethyl-, 3-((1S)-1-(dimethylamino)ethyl)phenyl ester;NS00000463;Rivastigmina;3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate;Prometax (TN);DB00989;RIVASTIGMINE 1 A PHARMA;GTPL6602;HMS2089H18;W-200966;(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate;NCGC00167531-17;3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate;RIVASTIGMINE (USP-RS);Rivastigmine (JAN/USP/INN);SR-05000001475-1;(S)-3-(1-(dimethylamino)ethyl)phenyl ethyl(methyl)carbamate;CS-0946;D82061;3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl N-methyl carbamate;RIVASTIGMINE [INN];SR-05000001475-2;Nimvastid;RIVASTIGMINE [MART.];RIVASTIGMINE [USP MONOGRAPH];(S)-N-ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate;rivastigmine;[3-[(1S)-1-dimethylaminoethyl]phenyl] N-ethyl-N-methylcarbamate;Rivastigmine sandoz;Ethylmethylcarbami...
SMILES: O=C(N(C)CC)OC1=CC=CC([C@H](C)N(C)C)=C1
Formula: C14H22N2O2
M.Wt: 250.34
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: An acetylcholinesterase (AChE) inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase; a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease.Alzheimer's DiseaseApproved
Cat. No. Product name Field of application
DC31074 Isopropyl myristate Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC79609 NCGC00685960 NCGC00685960 is a Nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 < 10  nM. NCGC00685960 has potent antitumor activity. NCGC00685960 increases H3K27 trimethylation levels in ovarian cancer cells and inhibits α-SMA expression in NNMT-expressing ovarian fibroblasts. NCGC00685960 reduces 1-MNA levels, reverses SAM and H3K27 hypomethylation and significantly impairs collagen contractility in cancer-associated fibroblasts (CAFs). NCGC00685960 can be used for cancers research.
DC77831 Vicadrostat Vicadrostat (compound 29 A) is a potent and selective inhibitor of aldosterone synthase(CYP11B2) with an IC50 of 16 nM. It exhibits potential in renal disease, diabetic nephropathy, cardiovascular diseases and fibrotic disorder research.
DC77813 Zeltociclib Zeltociclib is a cyclin-dependent kinase inhibitor with antitumor effects.
DC77714 S3226 S3226 is an inhibitor for Na+/H+ exchange subtype 3 (NHE3) with an IC50 of 0.2 µmol/L in rat NHE3 transfected fibroblasts. S3226 exhibits protective activity in rat ischemia-induced acute renal failure models.
DC77387 AUR1545 AUR1545 is a selective degrader of KAT2A and KAT2B. AUR1545 can be used in the cancer research, including studies on AML (Acute myeloid leukemia), SCLC (Small-cell carcinoma), and NEPC (Neuroendocrine Prostate Cancer).
DC77822 JNJ-77242113 (Icotrokinr) Icotrokinra (JNJ-77242113, JNJ-2113, PN-235) is an orally available and selective antagonist of the IL-23 receptor. It also inhibits IL-23–induced STAT3 phosphorylation in peripheral blood mononuclear cells with an IC50 of 5.6 pM and suppresses IL-23–induced IFN-γ production in NK cells with an IC50 of 18.4 pM. It also exhibits anti-inflammatory activity in a TNBS-induced colitis model in rats and holds potential for studying psoriasis, psoriatic arthritis, and inflammatory bowel disease.
DC77088 T025 T025 is as an orally available and potent inhibitor of Cdc2‐like kinases (CLKs) with an IC50s of 0.93 nM, 1 nM, 14 nM, 1.5 nM for CLK1, CLK2, CLK3, DYRK1B respectively. It exhibits anti‐tumor efficacy and can be used in MYC‐driven cancer research.
DC75868 AZ14133346 AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865 TI17 ​​TI17​​ represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
X